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Abstract Apoptosis in corpus luteum (CL) is induced by
prolactin (PRL) in female rats. PRL-induced apoptosis in CL
is mediated by the Fas/Fas ligand (FasL) system. The CL
consists of steroidogenic and non-steroidogenic cells, including
immunocytes. Fas mRNA was detected only in the luteal
steroidogenic cells, and FasL mRNA was expressed only by
the non-steroidogenic CD3-positive luteal immunocytes. Remov-
ing the luteal immune cells from the luteal cells inhibited PRL-
induced luteal cell apoptosis effectively. Thus, FasL-expressing
non-steroidogenic luteal immunocytes are required for PRL-
induced luteal cell apoptosis and heterogeneous induction of
apoptosis by Fas/FasL in CL.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
The regression of corpus luteum (CL) in female rats (luteol-
ysis), assessed by decreases in weight, size and steroidogenic
activity, has been shown to be dependent on the prolactin
(PRL) surge that occurs in the proestrous afternoon [1^4].
We previously found that this luteolysis was associated with
the occurrence of fragmented DNA degeneration, a hallmark
of apoptosis [5,6]. This apoptotic regression of CL seems to be
a suitable model for elucidating the processes of physiological
cell death.
The CL tissue consists of steroidogenic and non-steroido-
genic cells [7^18]. During luteinization, the steroidogenic fol-
licular granulosa and theca cells di¡erentiate to luteal steroi-
dogenic cells, and simultaneously endothelial and blood cells
migrate extensively into the newly formed CL tissue [13^17].
Progesterone is synthesized in and secreted from steroidogenic
luteal cells ; however, the maintenance of this function has
been believed to be supported by other cell populations such
as ¢broblast, endothelial, and blood cells [11,13^17,19,20].
Previous reports suggest the involvement of immune cells
during the process of PRL-induced luteolysis ; Bowen et al.
[21] reported the invasion of macrophages and an increased
expression of monocyte chemo-attractant protein-1 (MCP-1)
during PRL-induced CL regression, and PRL-induced luteol-
ysis was blocked by immunosuppressive levels of glucocorti-
coid [22] and a prostaglandin synthesis inhibitor [23]. Further-
more, recent observations revealed the correlation of the Fas/
Fas ligand (FasL) system with reproductive tissue remodeling
[24^28]. Fas is a cell surface molecule that mediates apoptosis-
inducing signals by stimulation with FasL or agonistic anti-
Fas antibody [29]. A signi¢cant amount of Fas is detected in
mammalian reproductive organs as well as in immune tissues
[24^27,30]. Our recent studies have demonstrated that PRL-
induced apoptosis at luteolysis is mediated by the Fas/FasL
system in rats [31]. Brie£y, FasL expression was enhanced by
PRL stimulation on cultured rat luteal cells, and PRL-induced
luteal cell death was inhibited by the addition of neutralizing
anti-FasL antibody [31]. We have also suggested the possible
roles of luteal immune cells in PRL-induced luteolysis, by the
observations that FasL expression in luteal cells was enhanced
by concanavalin A (ConA), a reagent for T-cell stimulation,
and that both CD3-positive and FasL-positive cells were co-
localized in regressing CL in discrete regions where apoptosis
occurred [31].
In this study, we de¢ned speci¢c cell populations that ex-
press FasL in CL and found that FasL and Fas receptor-
expressing cell populations in CL are dissociated. The FasL-
expressing cells are non-steroidogenic cells including CD3-
positive immune cells, which are therefore essential for
PRL-induced luteolysis. Our observations present a novel
physiological cell death involving FasL-expressing killer cells,
which results in such rapid tissue remodeling as regression of
CL.
2. Materials and methods
2.1. Animals
Adult female Wistar rats (12 weeks old) were housed under con-
trolled lighting conditions of 14 h light and 10 h darkness for 1^2
months (lights on 05.00^19.00 h). Vaginal cytological examination
was done every day, and only those animals that had shown consec-
utive regular 4-day cycles were used. Luteal cells were obtained from
8^14-week-old rats on the proestrous day as previously described [31].
2.2. Dispersion, separation and culture of luteal cells
Cells were prepared from CL by a modi¢ed method of Kuranaga et
al. [31]. Brie£y, a crop of newly formed CL were removed from 8^14-
week-old rats at 18.00 h on the proestrous day and dispersed by
collagenase.
To separate luteal cells into populations based on size and gravity,
a modi¢ed Percoll gradient centrifugation (Pharmacia) method was
used according to the procedure of Saksela et al. [32]. Brie£y, dis-
persed cells in 3 ml Dulbecco’s modi¢ed Eagle’s medium (DMEM)
were quietly put on 3 ml 10% Percoll solution. The column was
centrifuged at 500 rpm at 4‡C for 7^9 min, until the large cell sub-
population of prepared cells moved into the Percoll solution. Fraction
1 was 2 ml of the top layer, and fraction 2 was 2 ml of the lower layer.
Each fraction was collected in a 15-ml tube and centrifuged at 1000
rpm at 4‡C for 10 min.
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The cells were seeded in 96-well plates at a density of 32 000 viable
cells/0.25 ml/well and cultured in a medium consisting of DMEM
supplemented with 10% fetal bovine serum, 20 mM HEPES, 50 IU/
ml penicillin, and 0.1 mg/ml streptomycin.
2.3. Detection of steroidogenic cells
Steroidogenic cells in cultured luteal cells were identi¢ed by both
3L-hydroxysteroid dehydrogenase (3L-HSD) and 20K-HSD activity
stainings. Each of the two cell populations was washed in phos-
phate-bu¡ered saline (PBS) and incubated with reactive solution in
PBS containing 1.16 mM nicotinamide, 0.18 mM nitroblue tetrazo-
lium, 0.72 mM L-NADP, 6.25% propylene glycol, 1.25 mM EDTA,
86.7 WM dehydroepiandrosterone (for 3L-HSD activity staining) or 10
mg/ml 20K-dihydroprogesterone (for 20K-HSD activity staining), and
0.1% bovine serum albumin for 60 min at 37‡C. The frequency of
steroidogenic cells was calculated by counting the number of blue-
stained cells in the total number of cells.
2.4. Western blotting
To characterize cell types in the large and small cell populations,
Western blotting was done with monoclonal anti-rat CD3 antibody, a
speci¢c antibody to rat T-lymphocytes, as previously reported by
Kuranaga et al. [31]. Samples were electrophoresed on a 15% polyac-
rylamide gel, and the protein was transferred to PVDF membranes
(Millipore). The membranes were incubated for 1 h at room temper-
ature with 1000-fold diluted anti-rat CD3 antibody (Cerotec), and
then incubated for 30 min at room temperature with 1000-fold diluted
peroxidase-conjugated rabbit anti-mouse IgG (A0207; Vector Labo-
ratories Inc.). The proteins recognized by the antibody were visualized
by the ECL system (Amersham).
2.5. Immunostaining
Small cells treated with Percoll were used for immunostaining. Cells
were immersed in 4% PFA in PBS and preincubated with 4% skim
milk in PBS. Then, cells were incubated with rabbit anti-rat FasL
antibody (C-178; Santa Cruz Biotechnology, Ltd.) (1:100) and anti-
CD3 monoclonal antibody (1F4; Cerotec) (1:100) diluted in skim
milk for 90 min at room temperature. Thereafter, small cells were
incubated with TRITC-conjugated swine anti-rabbit Ig (R-0156;
Dako) (1:100) and FITC-conjugated goat anti-mouse Ig (F-0479;
Dako) (1:100) for 60 min at room temperature.
2.6. Detection of Fas, FasL, 20K-HSD and PRL receptor (PRL-R)
mRNAs by RT-PCR
Expression of Fas, FasL, 20K-HSD and PRL-R mRNAs in the
cultured luteal cells was analyzed using RT-PCR. The TRIzol reagent
(Gibco BRL) was used to extract total RNA from cultured luteal
cells. cDNA was synthesized from 500 ng of total RNA using oligo-
d(T) (Perkin-Elmer) and Ready-to-Go You-Prime First-Strand Beads
(Promega, Annandale, NSW, Australia). For PCR analysis, the prim-
er sets for rat Fas (5P-GTG ATG AAG GGC ATG GTT-3P and 5P-
TTG ACA CGC ACC AGT CTT-3P), rat FasL (5P-CCA GAT CTA
CTG GGT AGA-3P and 5P-ATG GTC AGC AAC GGT AAG-3P),
rat 20K-HSD (5P-CTA GGG AAG AGC AGC ATC TGA-3P and 5P-
AGC AAG ACC AAC GGA TAC CAC-3P) and rat PRL-R (5P-TCT
CCA GCA GAT GGG TAT CAA AT-3P and 5P-GAG TGG GAG
ATC CAT TTT ACA GG-3P) were used. Reaction mixtures were
heated at 95‡C for 10 min, followed by 35 cycles of ampli¢cation
steps comprising 94‡C for 1 min, 55‡C for 1 min, and 72‡C for
2 min. Then the samples were incubated at 72‡C for 10 min. The
expected sizes of each PCR product were 546 bp (rat Fas), 698 bp
(rat FasL), 675 bp (rat 20K-HSD), and 632 bp (rat PRL-R). The
equality of the amount of cDNA samples used for PCR was veri¢ed
by PCR using the primer set for rat L-actin (Research Genetics, Inc).
The trials were repeated more than three times for each sample, and
representative results are shown.
2.7. Assay for cell viability
For cell viability assay, the amount of viable cells was assessed
using a Dojindo Cell Counting Kit including WST-1 (Dojindo) as
Fig. 1. Characterization of Percoll-treated rat luteal cells. A: Scheme of the Percoll-treated method. Dispersed luteal cells in 3 ml DMEM were
quietly put on 3 ml 10% Percoll solution, and the column was centrifuged until the large cell subpopulation in the prepared cells moved into
the Percoll solution. Fraction 1, 2 ml of the top layer (small cell fraction); fraction 2, 2 ml of the lower layer (large cell fraction). B: 3L-HSD
activity staining of small (right panel) and large (left panel) luteal cells after separation by Percoll treatment. C: The steroidogenic cells were
identi¢ed by 3L-HSD and 20K-HSD activity staining (mean þ S.E.M., n = 4, *P6 0.01 vs. large cells). D: Western blot analysis of CD3 in each
fraction. Cell lysates from each cell population were analyzed by immunoblotting with anti-CD3 antibody. CD3 protein was expressed in the
small cells but not in the large cells.
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previously described [31]. In this assay, data are expressed as percen-
tages of the appropriate control values.
2.8. Statistical analysis
Student’s t-test was used for statistical evaluation of the results.
Di¡erences of P6 0.05 were considered statistically signi¢cant.
3. Results
3.1. Characterization of the large and small cell fractions
To determine the cell that expresses Fas and FasL in CL,
we ¢rst intended to separate and characterize the subpopula-
tions of CL cells. As shown in Fig. 1A,B, dispersed luteal cells
were successfully dissociated according to cell size. To assess
which kind of cells were included in each cell fraction, ¢rst the
steroidogenic cells were identi¢ed by 3L-HSD and 20K-HSD
activity stainings. The large cell fraction consists mainly of
3L-HSD- and 20K-HSD-positive cells (53.92 þ 4.03% and
77.36 þ 6.12%, respectively), but in the small cell fraction,
these steroidogenic activities were exhibited only by a minor
part of the cells (3L-HSD; 0.01 þ 0.00%, 20K-HSD; 28.58 þ
5.62%, Fig. 1B,C). The mRNA of 20K-HSD was also mainly
detected in the large cell fraction (Fig. 2A).
Next, these two cell fractions were subjected to Western
blotting with anti-CD3 antibody for detecting immune cells,
especially peripheral T-cells, in the luteal tissue. The CD3
proteins were observed in the small cell fraction, but not in
the large cell fraction (Fig. 1D). These data suggest that most
steroidogenic cells in CL are separated into the large fraction,
and most of the luteal immunocytes, including CD3-positive
T-cells, are separated into the small cell fraction.
3.2. Di¡erential expression patterns of Fas and FasL mRNA in
the luteal cell populations
To de¢ne the expression of Fas and FasL mRNAs in either
the small or the large cell fraction, semi-quantitative RT-PCR
was performed, together with the expression of PRL receptor
(PRL-R) and progesterone receptor mRNAs, which are
known to be expressed in CL. As shown in Fig. 2A, abundant
Fas mRNA was expressed speci¢cally in the large cell frac-
tion, which was consistent with our previous result that luteal
cell apoptosis induced by PRL mainly occurs in steroidogenic
cells [31]. The fractionated small cell population, however,
expressed only FasL but not Fas mRNA (Fig. 2A), suggesting
that the small cell fraction includes killer-type cells that induce
cell death against Fas-expressing steroidogenic cells by FasL.
PRL receptor mRNA was detected in both large and small
cell fractions (Fig. 2A). Thus, FasL-expressing cells are di¡er-
ent from Fas-expressing cells in regressing CL; the former
may be killer-type immune cells and the latter may be steroi-
dogenic cells.
In addition, immunohistochemical analysis was performed
to identify FasL-expressing cells in the small cell fraction.
Immunohistochemical analysis revealed that most CD3-posi-
tive cells also expressed FasL (Fig. 2B). We also stained the
Fig. 2. Characterization of Fas and FasL contained in each cell fraction. A: Expressions of Fas, FasL, 20K-HSD and PRL receptor mRNA in
large and small cell fractions were con¢rmed using RT-PCR. Fas mRNA was detected only in the large cell fraction, and FasL mRNA was de-
tected only in the small cell fraction. 20K-HSD and PRL receptor were expressed in both large and small cell fractions. To reveal that each
sample nearly included equivalent mRNA, we measured the expression of L-actin mRNA. B: Immunostaining of the small cell fraction of lu-
teal cells. a: light phase, b: CD3 (green), c: FasL (red), d: merged (yellow). Arrowheads indicate the cells that express both CD3 and FasL. A
non-stained cell was observed in all panels (arrow).
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small cell fraction by ED1, a speci¢c marker for macrophages.
However, macrophage-like cells could not be detected in the
small cell fraction (data not shown). Thus, we suggest that
FasL is expressed in the CD3-positive luteal immune cells.
3.3. Small non-steroidogenic cells are required for PRL-induced
luteal cell apoptosis
To elucidate whether the small cell fraction containing
FasL-expressing cells is necessary for the luteal cell apoptosis
induced by PRL, the fractionated large cells were cultured
with or without the small cell fraction. Although a consider-
able decrease in cell viability was observed even in the absence
of PRL, the data in Fig. 3 are expressed as percentages of the
average viability in the absence of PRL to evaluate the PRL
e¡ect in vitro. The large steroidogenic cells co-cultured with
small cells were rendered apoptotic by the addition of PRL
(Fig. 3A) exactly as was observed in a whole cell culture
[31,42]. However, PRL induced apoptosis in neither the frac-
tionated large cell culture nor the fractionated small cell cul-
ture (Fig. 3B,C). We con¢rmed that the large steroidogenic
cells did not express FasL mRNA by PRL addition after the
culture period (data not shown). These data strongly indicate
that the FasL-expressing small cells containing luteal immu-
nocytes are required for PRL to induce apoptosis in steroido-
genic cells.
4. Discussion
The present study shows the ¢rst clear demonstration of a
physiological role for luteal non-steroidogenic cells, which are
required for inducing apoptosis in luteal steroidogenic cells.
The CL is a heterogeneous tissue consisting of steroidogenic
and non-steroidogenic cells [12^18]. The separation of luteal
cells has been done for di¡erent intentions to obtain large and
small steroidogenic cell populations [18,33^36]. In this work,
however, our intention was to separate non-steroidogenic cells
from the steroidogenic luteal cell population, and we suc-
ceeded in separating the non-steroidogenic cell population
into the ‘small cell fraction’ ; most of the steroidogenic cell
population was segregated into the ‘large cell fraction’. It is
noteworthy that expression of CD3 (a marker for peripheral
T-cells) was only detected in the small cell fraction, suggesting
that the small cell fraction contained immunocytes. Thus,
we considered that these two subpopulations are useful
for evaluating the exact roles of luteal immune cells in the
process of apoptotic cell death in steroidogenic cells during
luteolysis.
In cycling rats in which ovulation recurs at 4^5-day inter-
vals, CL tissue never acquires the activity for maintaining
continuous progesterone secretion [37^39]. This process has
been described as structural luteolysis, and we recently re-
vealed that structural luteolysis is initiated by apoptosis in
luteal steroidogenic cells induced by PRL [31]. Because the
Fig. 3. Small cell fraction is required for PRL-induced luteal cell
apoptosis. Large fractionated cells were cultured with or without
the small cell fraction in the presence of PRL (2 Wg/ml). Luteal cells
were cultured for 24 h. Cell viability was measured by MTT assay.
The results are expressed as percentages of the average viability in
the absence of PRL (mean þ S.E.M., n = 4 *P6 0.01 vs. control). A:
Large steroidogenic cells were co-cultured with small cells, and were
induced to apoptosis by PRL stimulation. Single cultured large frac-
tionated cells (B) and small fractionated cells (C) were not induced
to apoptosis by PRL stimulation.
Fig. 4. A model for the role of luteal large (steroidogenic) and small
(non-steroidogenic) cells in luteal cell apoptosis and the outline of a
predicted mechanism for CL regression. The FasL expression is en-
hanced by PRL stimulation on the non-steroidogenic cells. Then,
the non-steroidogenic cells (mainly immunocytes) expressing FasL
interact with Fas-expressing steroidogenic cells and induce apoptotic
cell death in steroidogenic cells.
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Fas/FasL system is required for this PRL-induced luteal cell
apoptosis as we previously reported [31], luteal steroidogenic
cells seem to be one of the candidates that express Fas to
receive a cell death trigger, FasL. The present results indicate
that CL cells in the way of regression can be classi¢ed into
two cell populations according to their expressing molecules,
Fas and FasL. The cells expressing Fas mRNA were included
in the steroidogenic cell-rich population, and those expressing
FasL mRNA were included in the non-steroidogenic cell pop-
ulation. In addition, immunohistochemical suggests that CD3-
positive luteal immunocytes express FasL. Thus, although the
possibility that fractionated small cells other than immuno-
cytes also express FasL cannot be ruled out, the presence of
non-steroidogenic luteal immune cells expressing FasL seems
a prerequisite to induce apoptosis in Fas-expressing steroido-
genic cells.
Although we previously showed the functional correlation
of the Fas/FasL system with PRL-induced CL regression, it
had remained to be elucidated whether or not the e¡ector cells
(with FasL) are identical to the recipient cells (with Fas):
heterogenic or homogenic induction of apoptosis in CL re-
gression. Because the addition of ConA as well as PRL en-
hances the expression of FasL protein in primary luteal cell
culture [31], and because the morphological Fas expression
pattern is clearly associated with the CD3-positive region in
regressing CL [31], the cells that respond to PRL and express
FasL have been suggested to be luteal immunocytes. In the
present study, the following were found: (1) FasL-positive
cells were speci¢cally included in the small cell fraction where
a majority of the cells were identi¢ed as non-steroidogenic
cells ; (2) CD3-positive cells in the small cell fraction express
FasL proteins; and (3) the small cell fraction did not express
Fas entirely. Thus, we conclude that during the course of
structural luteolysis, the steroidogenic cells are killed by
FasL-expressing luteal immune cells, but not by themselves.
This style of apoptosis could be considered a non-cell auton-
omous form that resembles the immune response with the
Fas/FasL system by cytotoxic T-cells.
By cell separation, we revealed that luteal non-steroidogenic
cells are required for PRL-induced CL regression. Although
some previous reports suggest that luteal immune cells may be
required for the PRL-induced regression of CL by the use of
immunosuppressive reagents [22,40,41], there remained other
possibilities in causing damage to other tissues/cells or cell
toxicity by these reagents, resulting in the arti¢cial blockade
of PRL-induced CL regression. Here we clearly showed that
PRL-induced luteal cell apoptosis was inhibited in luteal cell
culture without immune cells. Thus, it is directly suggested
that the occurrence of luteal cell apoptosis requires the func-
tions of luteal immune cells. This result also reinforces the
notion that luteal cell apoptosis should be mediated by the
Fas/FasL system. Based on these ¢ndings and previous obser-
vations [31,42], we can illustrate the predicted form of luteal
cell apoptosis as follows (Fig. 4): in the regressing CL, (1) the
steroidogenic cells express Fas on the surface on the cells’ own
surface, (2) PRL binds its receptor on luteal immune cells and
induces the expression of FasL on the surface of this kind of
cell, and (3) the cells expressing FasL interact with Fas-ex-
pressing steroidogenic cells and induce apoptotic cell death in
steroidogenic cells rapidly.
In summary, we suggest that the FasL-expressing luteal
immune cells are required for PRL-induced luteal cell apop-
tosis in the regressing CL. The Fas/FasL system in CL oper-
ates between the steroidogenic cells and the immune cells.
These ¢ndings pose a novel fashion of physiological cell death
using the Fas/FasL system in the remodeling of peripheral
tissues, and can be implicated in other, unknown regulations
of physiological apoptosis.
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